CA2551859A1 - Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof - Google Patents
Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof Download PDFInfo
- Publication number
- CA2551859A1 CA2551859A1 CA002551859A CA2551859A CA2551859A1 CA 2551859 A1 CA2551859 A1 CA 2551859A1 CA 002551859 A CA002551859 A CA 002551859A CA 2551859 A CA2551859 A CA 2551859A CA 2551859 A1 CA2551859 A1 CA 2551859A1
- Authority
- CA
- Canada
- Prior art keywords
- attached
- carbon
- stereochemistry
- configuration
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
Abstract
Methods for synthesis of 1-(acyloxy)-alkyl carbamates, particularly, the synthesis of 1-(acyloxy)-alkyl carbamate prodrugs of primary or secondary amine containing drugs are described. Also described are methods for synthes is of 1-(acyloxy)-alkyl N-hydroxysuccinimidyl carbonates which are useful intermediates in the synthesis of 1-(acyloxy)-alkyl carbamates are also described.
Claims (84)
1. A method of synthesizing a 1-(acyloxy)-aryl N-hydroxysuccinimidyl carbonate compound of Formula (I), comprising:
(i) contacting a compound of Formula (IV) and a compound of Formula (V) to provide a compound of Formula (VI);
(ii) contacting the compound of Formula (VI) with a carboxylate compound of Formula (VII) to provide an acyloxyalkyl thiocarbonate compound of Formula (VIII);
and (iii) contacting the thiocarbonate compound of Formula (VIII) with an oxidant (IX), in the presence of an N-hydroxysuccinimide compound of Formula (X) to afford the compound of Formula (I);
wherein:
X is Cl,Br or I;
B1+ is an alkali metal cation, a quaternary ammonium cation, or the conjugate acid of an organic-base;
B2+ is a quaternary ammonium cation, the conjugate acid of an organic base, an alkali metal cation, or an alkaline earth metal canon;
R1 is alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;
R2 and R3 are independently hydrogen, alkyl, substituted alkyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl, or optionally, R2 and R3 together with the atom to which they are bonded form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl or substituted cycloheteroalkyl ring;
R4 is C1-4 alkyl, phenyl, substituted phenyl or C7-9 phenylalkyl; and R5 and R6 are independently hydrogen, acylamino, acyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, carbamoyloxy, dialkylamino, heteroaryl, hydroxy, sulfonamido, or optionally, R5 and R6 together with the atoms to which they are attached form a substituted cycloalkyl, substituted cycloheteroalkyl, or substituted aryl ring.
(i) contacting a compound of Formula (IV) and a compound of Formula (V) to provide a compound of Formula (VI);
(ii) contacting the compound of Formula (VI) with a carboxylate compound of Formula (VII) to provide an acyloxyalkyl thiocarbonate compound of Formula (VIII);
and (iii) contacting the thiocarbonate compound of Formula (VIII) with an oxidant (IX), in the presence of an N-hydroxysuccinimide compound of Formula (X) to afford the compound of Formula (I);
wherein:
X is Cl,Br or I;
B1+ is an alkali metal cation, a quaternary ammonium cation, or the conjugate acid of an organic-base;
B2+ is a quaternary ammonium cation, the conjugate acid of an organic base, an alkali metal cation, or an alkaline earth metal canon;
R1 is alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl;
R2 and R3 are independently hydrogen, alkyl, substituted alkyl, alkoxycarbonyl, substituted alkoxycarbonyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, carbamoyl, substituted carbamoyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl or substituted heteroarylalkyl, or optionally, R2 and R3 together with the atom to which they are bonded form a cycloalkyl, substituted cycloalkyl, cycloheteroalkyl or substituted cycloheteroalkyl ring;
R4 is C1-4 alkyl, phenyl, substituted phenyl or C7-9 phenylalkyl; and R5 and R6 are independently hydrogen, acylamino, acyloxy, alkoxycarbonylamino, alkoxycarbonyloxy, alkyl, substituted alkyl, alkoxy, substituted alkoxy, aryl, substituted aryl, arylalkyl, carbamoyloxy, dialkylamino, heteroaryl, hydroxy, sulfonamido, or optionally, R5 and R6 together with the atoms to which they are attached form a substituted cycloalkyl, substituted cycloheteroalkyl, or substituted aryl ring.
2. The method of Claim 1, wherein X is Cl.
3. The method of Claim 1, wherein R1 is selected from the group consisting of C1-6 alkyl, substituted C1-6 alkyl, C3-6 cycloalkyl, phenyl, substituted phenyl and C7-9 phenylalkyl.
4. The method of Claim 3, wherein R1 is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl, 1,1-diethoxyethyl, phenyl or cyclohexyl.
5. The method of Claim 1, wherein R2 and R3 are independently selected from the group consisting of hydrogen, C1-4 alkyl, substituted C1-4 alkyl, C1-alkoxycarbonyl, C3-6 cycloalkyl, C3-6 cycloalkoxycarbonyl, phenyl, substituted phenyl and C7-9 phenylalkyl.
6. The method of Claim 5, wherein R2 is hydrogen, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, phenyl or cyclohexyl and R3 is hydrogen.
7. The method of Claim 5, wherein R2 is methyl, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl or cyclohexyloxycarbonyl and R3 is methyl.
8. The method of Claim 1, wherein R2 and R3 together with the carbon atom to which they are attached form a cyclobutyl, cyclopentyl or cyclohexyl ring.
9. The method of Claim 1, wherein R4 is methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, test-butyl, phenyl, 4-methoxyphenyl, 4-methylphenyl or benzyl.
10. The method of Claim 1, wherein R5 and R6 are both hydrogen.
11. The method of Claim 1, wherein R5 and R6 are each acyloxy, alkoxycarbonyloxy, alkoxy, carbamoyloxy or hydroxy.
12. The method of Claim 11, wherein R5 and R6 are each acetoxy, isobutyroyloxy, pivaloyloxy, benzoyloxy, C1-4 alkyl-substituted benzoyloxy, methoxy or benzyloxy.
13. The method of Claim 12, wherein R5 and R6 are each isobutyroyloxy or benzoyloxy.
14. The method of Claim 1, wherein R1 is isopropyl, R2 is methyl, R3 is hydrogen, R4 is methyl, ethyl or tert-butyl, and R5 and R6 are each hydrogen.
15. The method of Claim 1, wherein R1 is isopropyl, R2 is isopropyl, R3 is hydrogen, R4 is methyl, ethyl or tert-butyl, and R5 and R6 are each benzoyloxy.
16. The method of Claim 1, wherein R1 is isopropyl, R2 is isopropyl, R3 is hydrogen, R4 is methyl, ethyl or tert-butyl, and R5 and R6 are each isobutyroyloxy.
17. The method of Claim 1, wherein R1 is isopropyl, R2 is isopropyl, R3 is hydrogen, R4 is methyl, ethyl or tert-butyl, and R5 and R6 are each pivaloyloxy.
18. The method of Claim 1, wherein R1 is isopropyl, R2 is isopropyl, R3 is hydrogen, R4 is methyl, ethyl or tert-butyl, and R5 and R6 are each C1-4 alkyl-substituted benzoyloxy.
19. The method of Claim 1, wherein R2 and R3 in the compound of Formula (I) are different, such that the carbon atom to which R2 and R3 are attached is a stereogenic center.
20. The method of Claim 19, wherein the compound of Formula (X) is chiral and non-racemic.
21. The method of Claim 20, wherein R5 and R6 in the compound of Formula Formula (X) are each isobutyryloxy or benzoyloxy, the stereochemistry at the carbon to which R5 is attached is of the R-configuration, and the stereochemistry at the carbon to which R6 is attached is of the R-configuration.
22. The method of Claim 20, wherein R5 and R6 in the compound of Formula Formula (X) are each isobutyryloxy or benzoyloxy, the stereochemistry at the carbon to which R5 is attached is of the S-configuration, and the stereochemistry at the carbon to which R6 is attached is of the S-configuration.
23. The method of Claim 20, wherein the compound of Formula (I) comprises substantially one diastereomer.
24. The method of Claim 23, wherein R1 is isopropyl, R2 is isopropyl, R3 is hydrogen, R4 is methyl, ethyl or tert-butyl, R5 and R6 are each benzoyloxy, the stereochemistry at the carbon to which R2 and R3 are attached is of the S-configuration, the stereochemistry at the carbon to which R5 is attached is of the R-configuration, and the stereochemistry at the carbon to which R6 is attached is of the R-configuration.
25. The method of Claim 23, wherein R1 is isopropyl, R2 is isopropyl, R3 is hydrogen, R4 is methyl, ethyl or teat-butyl, R5 and R6 are each benzoyloxy, the stereochemistry at the carbon to which R2 and R3 are attached is of the R-configuration, the stereochemistry at the carbon to which R5 is attached is of the S-configuration, and the stereochemistry at the carbon to which R6 is attached is of the S-configuration.
26. The method of Claim 23, wherein R1 is isopropyl, R2 is isopropyl, R3 is hydrogen, R4 is methyl, ethyl or tert-butyl, R5 and R6 are each isobutyroyloxy, the stereochemistry at the carbon to which R2 and R3 are attached is of the R-configuration, the stereochemistry at the carbon to which R5 is attached is of the R-configuration, and the stereochemistry at the carbon to which R6 is attached is of the R-configuration.
27. The method of Claim 23, wherein R1 is isopropyl, R2 is isopropyl, R3 is hydrogen, R4 is methyl, ethyl or tert-butyl, R5 and R6 are each isobutyroyloxy, the stereochemistry at the carbon to which R2 and R3 are attached is of the S-configuration, the stereochemistry at the carbon to which R5 is attached is of the S-configuration, and the stereochemistry at the carbon to which R6 is attached is of the S-configuration.
28. The method of Claim 1, wherein B1+ of Formula (V) comprises an alkali metal canon.
29. The method of Claim 28, wherein B1+ of Formula (V) comprises a sodium ion.
30. The method of Claim 1, wherein B1+ of Formula (V) comprises a cation selected from the group consisting of tetramethylammonium, tetraethylammonium, tetrabutylammonium, triethylammonium, diisopropylethylammonium, N-methylinorpholinium and pyridinium.
31. The method of Claim 1, wherein step (iii) is carried out in the presence of a base.
32. The method of Claim 1, wherein step (i) is carried out in the presence of a solvent selected from the group consisting of dichloromethane, dichloroethane, chloroform, toluene, tetrahydrofuran, dioxane, dimethylformamide, dimethylacetamide, N-methylpyrrolidinone, dimethyl sulfoxide, pyridine, ethyl acetate, acetonitrile, methyl tert-butyl ether, water and combinations thereof.
33. The method of Claim 32, wherein the solvent comprises dichloromethane, water or a combination thereof.
34. The method of Claim 33, wherein the solvent comprises a biphasic mixture of dichloromethane and water containing from about 0.001 equivalents to about 0.1 equivalents of a tetraalkylammonium salt phase transfer catalyst.
35. The method of Claim 32, wherein step (i) is carried out at a temperature between about -20 °C and about 25 °C.
36. The method of Claim 35, wherein step (i) is carried out at a temperature between about 0 °C and about 25 °C.
37. The method of Claim 1, wherein B2+ of Formula (VII) is a cation selected from the group consisting of tetramethylammonium, tetraethylammonium, tetrabutylammonium, triethylammonium, diisopropylethylammonium, N-methylmorpholinium and pyridinium.
38. The method of Claim 1, wherein B2+ of Formula (VII) comprises a lithium, sodium or potassium ion.
39. The method of Claim 1, wherein step (ii) is carried out in the presence of a solvent selected from the group consisting of tetrahydrofuran, dioxane, dichloromethane, toluene, pyridine, methyl tert-butyl ether, methanol, ethanol, isopropanol, water, the conjugate acid of the compound of Formula (VII) and combinations thereof.
40. The method of Claim 39, wherein step (ii) is carried out at a temperature between about -20 °C and about 100 °C.
41. The method of Claim 1, wherein the oxidant (IX) comprises a composition selected from the group consisting of a peroxy acid, a peroxide, ozone and oxygen.
42. The method of Claim 41, wherein the peroxy acid is selected from the group consisting of peroxyacetic acid, m-chloroperoxybenzoic acid, monoperoxy-o-phthalic acid, monoperoxymaleic acid, peroxytrifluoroacetic acid and salts thereof.
43. The method of Claim 42, wherein the peroxy acid comprises peroxyacetic acid.
44. The method of Claim 41, wherein the oxidant (IX) and the thiocarbonate (VIII) are present in a molar ratio of oxidant (IX) : thiocarbonate (VIII) of between about 10:1 and about 1:1.
45. The method of Claim 44, wherein the molar ratio is between about 3: 1 and about 1:1.
46. The method of Claim 1, wherein step (iii) is carried out in the presence of a solvent selected from the group consisting of acetic acid, dichloromethane, dichloroethane, chloroform, ethyl acetate, toluene, chlorobenzene, xylene, acetonitrile, methyl tert-butyl ether, cyclohexane or combinations thereof.
47. The method of Claim 46, wherein the solvent comprises acetic acid, dichloromethane or combinations thereof.
48. The method of Claim 46, wherein step (iii) is carried out at a temperature between about -20 °C and about 80 °C.
49. The method of Claim 48, wherein step (iii) is carried out at a temperature between about -20 °C and about 25 °C.
50. The method of Claim 48, wherein step (iii) is carried out a temperature between about 25 °C and about 60 °C.
51. The method of Claim 1, wherein step (iii) is carried out in the absence of a base.
52. A compound of Formula (I), and salts and solvates thereof, wherein:
R1 is isopropyl;
R2 is methyl;
R3 is hydrogen; and R5 and R6 are each hydrogen.
R1 is isopropyl;
R2 is methyl;
R3 is hydrogen; and R5 and R6 are each hydrogen.
53. A compound of Formula (I), and salts and solvates thereof, wherein:
R1 is isopropyl;
R2 is isopropyl;
R3 is hydrogen; and R5 and R6 are each benzoyloxy.
R1 is isopropyl;
R2 is isopropyl;
R3 is hydrogen; and R5 and R6 are each benzoyloxy.
54. A compound of Formula (I), and salts and solvates thereof, wherein:
R1 is isopropyl;
R2 is isopropyl;
R3 is hydrogen; and R5 and R6 are each isobutyroyloxy.
R1 is isopropyl;
R2 is isopropyl;
R3 is hydrogen; and R5 and R6 are each isobutyroyloxy.
55. The compound of Claim 53, wherein the stereochemistry at the carbon to which R2 and R3 are attached is of the S-configuration, the stereochemistry at the carbon to which R5 is attached is of the R-configuration, and the stereochemistry at the carbon to which R6 is attached is of the R-configuration.
56. The compound of Claim 53, wherein the stereochemistry at the carbon to which R2 and R3 are attached is of the R-configuration, the stereochemistry at the carbon to which R5 is attached is of the S-configuration, and the stereochemistry at the carbon to which R6 is attached is of the S-configuration.
57. The compound of Claim 54, wherein the stereochemistry at the carbon to which R2 and R3 are attached is of the S-configuration, the stereochemistry at the carbon to which R5 is attached is of the S-configuration, and the stereochemistry at the carbon to which R6 is attached is of the S-configuration.
58. The compound of Claim 54, wherein the stereochemistry at the carbon to which R2 and R3 are attached is of the R-configuration, the stereochemistry at the carbon to which R5 is attached is of the R-configuration, and the stereochemistry at the carbon to which R6 is attached is of the R-configuration.
59. The method of Claim 1, further comprising:
(iv) contacting the compound of Formula (I) with a primary or secondary amine-containing drug of Formula (II) to afford a compound of Formula (III) or a pharmaceutically acceptable salt, hydrate or solvate thereof;
wherein:
HNR7R8 is a primary or secondary amine-containing drug.
(iv) contacting the compound of Formula (I) with a primary or secondary amine-containing drug of Formula (II) to afford a compound of Formula (III) or a pharmaceutically acceptable salt, hydrate or solvate thereof;
wherein:
HNR7R8 is a primary or secondary amine-containing drug.
60. The method of Claim 59, wherein HNR7R8 is gabapentin.
61. The method of Claim 60, wherein R1 is isopropyl, R2 is methyl, R3 is hydrogen, R4 is methyl, ethyl or tert-butyl, and R5 and R6 are each hydrogen.
62. The method of Claim 59, wherein HNR7R8 is R-baclofen.
63. The method of Claim 62, wherein R1 is isopropyl, R2 is isopropyl, R3 is hydrogen, R4 is methyl, ethyl or tert-butyl, and R5 and R6 are each benzoyloxy.
64. The method of Claim 63, wherein the stereochemistry at the carbon to which R2 and R3 are attached is of the S-configuration, the stereochemistry at the carbon to which R5 is attached is of the R-configuration, and the stereochemistry at the carbon to which R6 is attached is of the R-configuration.
65. The method of Claim 63, wherein the stereochemistry at the carbon to which R2 and R3 are attached is of the R-configuration, the stereochemistry at the carbon to which R5 is attached is of the S-configuration, and the stereochemistry at the carbon to which R6 is attached is of the S-configuration.
66. The method of Claim 62, wherein R1 is isopropyl, R2 is isopropyl, R3 is hydrogen, R4 is methyl, ethyl or tert-butyl, and R5 and R6 are each isobutyroyloxy.
67. The method of Claim 66, wherein the stereochemistry at the carbon to which R2 and R3 are attached is of the S-configuration, the stereochemistry at the carbon to which R5 is attached is of the S-configuration, and the stereochemistry at the carbon to which R6 is attached is of the S-configuration.
68. The method of Claim 66, wherein the stereochemistry at the carbon to which R2 and R3 are attached is of the R-configuration, the stereochemistry at the carbon to which R5 is attached is of the R-configuration, and the stereochemistry at the carbon to which R6 is attached is of the R-configuration.
69. The method of Claim 59, wherein step (iv) is conducted in the presence of a solvent selected from the group consisting of acetone, acetonitrile, dichloromethane, toluene, tetrahydrofuran, pyridine, methyl tert-butyl ether, methanol, ethanol, isopropanol, water, and combinations thereof.
70. The method of Claim 69, wherein the solvent comprises a mixture of acetonitrile and water.
71. The method of Claim 70, wherein the acetonitrile and water are present in a volume ratio of acetonitrile : water from about 1:5 to about 5:1.
72. The method of Claim 69, wherein the solvent is a mixture of methyl tent-butyl ether and water.
73. The method of Claim 72, wherein the methyl tert-butyl ether and water are present in a volume ratio of methyl tert-butyl ether : water from about 20:1 to about 2:1.
74. The method of Claim 73, wherein the methyl tert-butyl ether contains from about 10% to about 50% acetone by volume.
75. The method of Claim 59, wherein step (iv) is carried out at a temperature between about -20 °C and about 40 °C.
76. The method of Claim 75, wherein step (iv) is carried out at a temperature between about 0 °C and about 25 °C.
77. The method of Claim 75, wherein step (iv) is carried out at a temperature of about 25 °C.
78. The method of Claim 59, wherein step (iv) is performed in the absence of a base.
79. The method of Claim 59, wherein step (iv) is performed in the presence of a base.
80. The method of Claim 79, wherein the base is an alkali metal bicarbonate or alkali metal carbonate salt.
81. The method of Claim 79, wherein the base is an organic base selected from the group consisting of triethylamine, diisopropylethylamine, N-methylmorpholine, and pyridine.
82. A method of synthesizing a 1-(acyloxy)-alkyl carbamate compound of Formula (XI) comprising contacting a compound of Formula (I) with gabapentin or a salt, or solvate thereof wherein R1, R2, R3, R5 and R6 are as defined in Claim 1.
83. A method of synthesizing a 1-(acyloxy)-alkyl carbamate compound of Formula (XII) comprising contacting a compound of Formula (I) with baclofen or a salt, or solvate thereof wherein R1, R2, R3, R5 and R6 are as defined in Claim 1.
84. A method of synthesizing a 1-(acyloxy)-alkyl carbamate compound of Formula (XIII) comprising contacting a compound of Formula (I) with R-(-)-baclofen or a salt, or solvate thereof wherein R1, R2, R3, R5 and R6 are as defined in Claim 1.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53364903P | 2003-12-30 | 2003-12-30 | |
| US60/533,649 | 2003-12-30 | ||
| US60663704P | 2004-08-13 | 2004-08-13 | |
| US60/606,637 | 2004-08-13 | ||
| PCT/US2004/043823 WO2005066122A2 (en) | 2003-12-30 | 2004-12-30 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2551859A1 true CA2551859A1 (en) | 2005-07-21 |
| CA2551859C CA2551859C (en) | 2011-10-04 |
Family
ID=34753006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2551859A Active CA2551859C (en) | 2003-12-30 | 2004-12-30 | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US7227028B2 (en) |
| EP (2) | EP2371815A1 (en) |
| JP (2) | JP4927563B2 (en) |
| CN (1) | CN102702065A (en) |
| CA (1) | CA2551859C (en) |
| DK (1) | DK1716115T3 (en) |
| ES (1) | ES2405329T3 (en) |
| HK (1) | HK1090924A1 (en) |
| IL (2) | IL176341A (en) |
| WO (1) | WO2005066122A2 (en) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
| US7025745B2 (en) * | 2002-10-07 | 2006-04-11 | Advanced Cardiovascular Systems, Inc. | Method of making a catheter balloon using a tapered mandrel |
| US7662987B2 (en) * | 2003-07-15 | 2010-02-16 | Xenoport, Inc. | Methods for synthesis of acyloxyalkyl compounds |
| PT1660440E (en) * | 2003-08-20 | 2012-05-15 | Xenoport Inc | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
| EP1670451A4 (en) * | 2003-09-11 | 2009-10-21 | Xenoport Inc | Treating and/or preventing urinary incontinence using prodrugs of gaba analogs |
| MXPA06004088A (en) * | 2003-10-14 | 2006-06-27 | Xenoport Inc | Crystalline form of gamma-aminobutyric acid analog. |
| JP4927563B2 (en) | 2003-12-30 | 2012-05-09 | ゼノポート，インコーポレイティド | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates |
| WO2006047302A1 (en) * | 2004-10-21 | 2006-05-04 | Transtech Pharma, Inc. | Bissulfonamide compounds as agonists of galr1, compositions, and methods of use |
| US7494985B2 (en) | 2004-11-03 | 2009-02-24 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use |
| KR101228399B1 (en) | 2004-11-04 | 2013-01-31 | 제노포트 인코포레이티드 | Gabapentin prodrug sustained release oral dosage forms |
| CN101253148B (en) | 2005-06-20 | 2013-01-02 | 克塞诺波特公司 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use |
| WO2007085933A2 (en) * | 2006-01-25 | 2007-08-02 | Glenmark Pharmaceuticals Limited | Process for the preparation of n-[1-(s)-ethoxycarbonyl-1-butyl]-(s)-alanine-dmt complex and its use in the preparation of perindopril |
| TW200820963A (en) * | 2006-07-28 | 2008-05-16 | Xenoport Inc | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use |
| US7585996B2 (en) | 2006-09-15 | 2009-09-08 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
| CA2674610C (en) * | 2007-01-11 | 2013-06-18 | Xenoport, Inc. | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
| US20090118365A1 (en) * | 2007-11-06 | 2009-05-07 | Xenoport, Inc | Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain |
| WO2009094563A2 (en) * | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Crystalline form of calcium-salts of (3s)-aminomethyl-b-methyl-hexanoic acids and methods of use |
| JP5563483B2 (en) * | 2008-01-25 | 2014-07-30 | ゼノポート，インコーポレイティド | Enantiomeric degradation of acyloxyalkyl thiocarbonates used in the synthesis of acyloxyalkyl carbamate prodrugs. |
| WO2009094577A2 (en) * | 2008-01-25 | 2009-07-30 | Xenoport, Inc. | Mesophasic forms of (3s)-aminomethyl-5-methyl-hexanoic acid prodrugs and methods of use |
| WO2009096985A1 (en) * | 2008-02-01 | 2009-08-06 | Xenoport, Inc. | Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment |
| US20100137442A2 (en) * | 2008-02-01 | 2010-06-03 | Xenoport, Inc. | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment |
| SG176464A1 (en) * | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| WO2010008886A2 (en) * | 2008-06-24 | 2010-01-21 | Teva Pharmaceutical Industries Ltd. | Processes for preparing prodrugs of gabapentin and intermediates thereof |
| TW201006789A (en) * | 2008-07-02 | 2010-02-16 | Teva Pharma | Gabapentin enacarbil salts and processes for their preparation |
| US8299291B2 (en) * | 2008-08-07 | 2012-10-30 | Xenoport, Inc. | Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs |
| US7989641B2 (en) | 2008-08-07 | 2011-08-02 | Xenoport, Inc. | Methods of synthesizing N-hydroxysuccinimidyl carbonates |
| WO2010063002A2 (en) * | 2008-11-26 | 2010-06-03 | Teva Pharmaceutical Industries Ltd. | Processes for the preparation and purification of gabapentin enacarbil |
| US20100160666A1 (en) * | 2008-12-23 | 2010-06-24 | Teva Pharmaceutical Industries Ltd. | Preparation of gabapentin enacarbil intermediate |
| CN102341099A (en) | 2009-03-03 | 2012-02-01 | 什诺波特有限公司 | Sustained release oral dosage forms of an R-baclofen prodrug |
| AU2010221167B2 (en) | 2009-03-06 | 2014-04-03 | Xenoport, Inc. | Oral dosage forms having a high loading of a gabapentin prodrug |
| JP2012524065A (en) * | 2009-04-17 | 2012-10-11 | ゼノポート，インコーポレーテッド | Γ-aminobutyric acid derivatives as GABAB receptor ligands |
| WO2011012721A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Carrier linked pramipexole prodrugs |
| WO2011012723A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Injectable sustained release compositions comprising a pramipexole prodrug |
| WO2011028234A1 (en) * | 2009-09-04 | 2011-03-10 | Xenoport, Inc. | Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid |
| US20110130454A1 (en) * | 2009-11-24 | 2011-06-02 | Xenoport, Inc. | Prodrugs of gamma-amino acid, alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| US20110124705A1 (en) * | 2009-11-24 | 2011-05-26 | Xenoport, Inc. | Prodrugs of alpha-2-delta ligands, pharmaceutical compositions and uses thereof |
| US20110184060A1 (en) | 2010-01-22 | 2011-07-28 | Xenoport, Inc. | Oral dosage forms having a high loading of a tranexamic acid prodrug |
| WO2011109403A1 (en) | 2010-03-01 | 2011-09-09 | Xenoport, Inc. | Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence |
| EP2937334B1 (en) * | 2010-03-10 | 2017-04-19 | Promentis Pharmaceuticals, Inc. | Propionic acids, propionic acid esters, and related compounds |
| DK2548871T3 (en) | 2010-03-18 | 2017-11-06 | Daiichi Sankyo Co Ltd | CYCLOAL COOL SUBSTITUTED IMIDAZOLD DERIVATIVE |
| US9248111B2 (en) | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| SI2727588T1 (en) | 2011-03-01 | 2019-03-29 | Pharnext | Baclofen and acamprosate based therapy of neurological disorders |
| UA115968C2 (en) | 2011-03-01 | 2018-01-25 | Фарнекст | NEW COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES |
| EP2705842A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| WO2013023155A1 (en) | 2011-08-11 | 2013-02-14 | Xenoport, Inc. | Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use |
| WO2013026777A1 (en) * | 2011-08-24 | 2013-02-28 | Solvay Sa | Fluoroalkyl s-(fluoro)alkyl thiocarbonates, a method for the preparation of fluoroalkyl s-(fluoro)alkyl thiocarbonates, and their use |
| CA2879114A1 (en) | 2012-07-18 | 2014-01-23 | Pharnext | Baclofen and acamprosate based therapy of macular degeneration disorders |
| EP2705843A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis |
| EP2705841A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Combinations of nootropic agents for treating cognitive dysfunctions |
| US20150158809A9 (en) | 2013-02-26 | 2015-06-11 | Xenoport, Inc. | Method of making 1-(acyloxy)-alkyl carbamate compounds |
| CN105683180B (en) | 2013-11-05 | 2020-01-21 | 阿斯利康(瑞典)有限公司 | NMDA antagonist prodrugs |
| US9394236B2 (en) | 2014-02-03 | 2016-07-19 | Quadriga Biosciences, Inc. | β-substituted γ-amino acids and analogs as chemotherapeutic agents |
| SG10201710436WA (en) | 2014-02-03 | 2018-01-30 | Quadriga Biosciences Inc | Beta-substituted beta-amino acids and analogs as chemotherapeutic agents |
| SG11201606275WA (en) | 2014-02-11 | 2016-08-30 | Pharnext | Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders |
| AU2015331904B2 (en) | 2014-10-17 | 2021-02-11 | The Board Of Trustees Of The University Of Illinois | Scalable synthesis of reduced toxicity derivative of amphotericin B |
| JPWO2016208709A1 (en) | 2015-06-26 | 2018-04-19 | 第一三共株式会社 | Novel process for producing 1- (acyloxy) alkylcarbamate derivatives |
| TWI665178B (en) | 2015-08-03 | 2019-07-11 | 夸德里加生物科學公司 | Beta-substituted beta-amino acid and analogue as chemotherapeutic agent and application thereof |
| EP3339291A1 (en) | 2016-12-22 | 2018-06-27 | Vita Api | Proteasome inhibiting ss-lactam prodrugs useful for the treatment of cancer and neurodegenerative disorders |
| CN111050761A (en) | 2017-04-24 | 2020-04-21 | 法奈克斯公司 | Idalopirdine-based combination therapy of alzheimer' s disease |
| CN108976147B (en) * | 2017-05-31 | 2021-02-12 | 首都医科大学 | Amino n-hexanoyl amido methyl-n-hexanoyl basic amino acid, synthesis, activity and application thereof |
| JP2021512174A (en) | 2018-01-29 | 2021-05-13 | ファーネクストＰｈａｒｎｅｘｔ | Therapy with baclofen and acamprosate for Alzheimer's disease in patients who have lost their responsiveness to acetylcholinesterase inhibitor therapy |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3262698D1 (en) | 1981-11-17 | 1985-04-25 | Kabivitrum Ab | Antifibrinolytically active compounds |
| US4426391A (en) * | 1982-09-15 | 1984-01-17 | Merck & Co., Inc. | [(Alkoxycarbonyl)oxy]alkyl esters of methyldopa |
| US4760057A (en) * | 1983-06-23 | 1988-07-26 | Merck & Co., Inc. | (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs |
| US4916230A (en) | 1984-07-02 | 1990-04-10 | Merck & Co., Inc. | Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs |
| JP2629375B2 (en) * | 1989-09-14 | 1997-07-09 | 日立化成工業株式会社 | Method for producing amino-protected dopa or dopa derivative |
| US5098999A (en) | 1989-08-23 | 1992-03-24 | Hitachi Chemical Company | Amino-protected dopa derivative and production thereof |
| DE69023844T2 (en) | 1989-09-06 | 1996-06-20 | Merck & Co Inc | Acyloxymethyl ester of bisphonic acids as bone resorption inhibitors. |
| GB9001405D0 (en) * | 1990-01-22 | 1990-03-21 | Leo Pharm Prod Ltd | New intermediates,their production and use |
| SE9200858L (en) | 1992-03-20 | 1993-09-21 | Kabi Pharmacia Ab | Method for producing delayed release pellets |
| SE9300013L (en) | 1992-12-30 | 1994-07-01 | Kabi Pharmacia Ab | New procedure and intermediates for the manufacture of prodrugs |
| IL111584A0 (en) | 1993-11-18 | 1995-01-24 | Merck & Co Inc | Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them |
| US5684018A (en) * | 1994-12-13 | 1997-11-04 | Merck & Co., Inc. | Acyloxyisopropyl carbamates as prodrugs for amine drugs |
| JPH10148903A (en) * | 1996-11-20 | 1998-06-02 | Konica Corp | Silver halide photographic sensitive material improved in pressure resistance |
| JP3526243B2 (en) | 1999-07-09 | 2004-05-10 | 松下電器産業株式会社 | Base station apparatus and line quality deterioration prevention method |
| EA200200161A1 (en) * | 1999-07-15 | 2002-06-27 | Эли Лилли Энд Компани | PROCARE OF PSEVDOMYCIN |
| GB2365425A (en) * | 2000-08-01 | 2002-02-20 | Parke Davis & Co Ltd | Alkyl amino acid derivatives useful as pharmaceutical agents |
| NZ567711A (en) * | 2001-06-11 | 2009-10-30 | Xenoport Inc | Orally administered dosage forms of GABA analog prodrugs having reduced toxicity |
| PT1660440E (en) * | 2003-08-20 | 2012-05-15 | Xenoport Inc | Acyloxyalkyl carbamate prodrugs, methods of synthesis and use |
| US7265140B2 (en) * | 2003-09-23 | 2007-09-04 | Pfizer Inc | Acyloxymethylcarbamate prodrugs of oxazolidinones |
| JP4927563B2 (en) | 2003-12-30 | 2012-05-09 | ゼノポート，インコーポレイティド | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates |
| WO2006050471A2 (en) | 2004-11-03 | 2006-05-11 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use |
| US7494985B2 (en) | 2004-11-03 | 2009-02-24 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use |
-
2004
- 2004-12-30 JP JP2006547532A patent/JP4927563B2/en active Active
- 2004-12-30 CN CN2012101837531A patent/CN102702065A/en active Pending
- 2004-12-30 WO PCT/US2004/043823 patent/WO2005066122A2/en active Application Filing
- 2004-12-30 EP EP11001106A patent/EP2371815A1/en not_active Ceased
- 2004-12-30 CA CA2551859A patent/CA2551859C/en active Active
- 2004-12-30 ES ES04815821T patent/ES2405329T3/en active Active
- 2004-12-30 DK DK04815821.6T patent/DK1716115T3/en active
- 2004-12-30 US US11/026,491 patent/US7227028B2/en active Active
- 2004-12-30 EP EP04815821A patent/EP1716115B1/en active Active
-
2006
- 2006-06-15 IL IL176341A patent/IL176341A/en active IP Right Grant
- 2006-11-16 HK HK06112592.1A patent/HK1090924A1/en not_active IP Right Cessation
-
2007
- 2007-05-25 US US11/754,232 patent/US7511158B2/en active Active
-
2009
- 2009-02-20 US US12/390,000 patent/US8003809B2/en active Active
- 2009-09-08 IL IL200821A patent/IL200821A/en active IP Right Grant
-
2011
- 2011-08-11 US US13/208,176 patent/US8378137B2/en active Active
- 2011-08-11 JP JP2011175796A patent/JP5670842B2/en not_active Expired - Fee Related
-
2013
- 2013-01-15 US US13/742,134 patent/US9353057B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20070037988A9 (en) | 2007-02-15 |
| JP2007518723A (en) | 2007-07-12 |
| US20090216037A1 (en) | 2009-08-27 |
| IL200821A (en) | 2013-03-24 |
| US9353057B2 (en) | 2016-05-31 |
| DK1716115T3 (en) | 2013-05-27 |
| ES2405329T3 (en) | 2013-05-30 |
| CA2551859C (en) | 2011-10-04 |
| US20070244331A1 (en) | 2007-10-18 |
| US20120010425A1 (en) | 2012-01-12 |
| WO2005066122A3 (en) | 2005-10-13 |
| JP5670842B2 (en) | 2015-02-18 |
| US7227028B2 (en) | 2007-06-05 |
| WO2005066122A2 (en) | 2005-07-21 |
| CN102702065A (en) | 2012-10-03 |
| HK1090924A1 (en) | 2007-01-05 |
| US7511158B2 (en) | 2009-03-31 |
| EP1716115A2 (en) | 2006-11-02 |
| US20130131355A1 (en) | 2013-05-23 |
| IL176341A (en) | 2013-03-24 |
| IL176341A0 (en) | 2008-02-09 |
| EP2371815A1 (en) | 2011-10-05 |
| US20050222431A1 (en) | 2005-10-06 |
| JP4927563B2 (en) | 2012-05-09 |
| US8378137B2 (en) | 2013-02-19 |
| JP2011236247A (en) | 2011-11-24 |
| US8003809B2 (en) | 2011-08-23 |
| EP1716115B1 (en) | 2013-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2551859A1 (en) | Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof | |
| ES2625628T3 (en) | Oxalic acid amides as neprilysin inhibitors, pharmaceutical composition based on them and their preparation | |
| ES2564275T3 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| ES2582640T3 (en) | Substituted aminobutyric derivatives as neprilysin inhibitors | |
| EP3307268B1 (en) | Substituted phenyloxazolidinones for antimicrobial therapy | |
| WO2008146871A1 (en) | Novel 1,2,3,4-tetrahydroquinoxaline derivative which has, as substituent, phenyl group having sulfonic acid ester structure or sulfonic acid amide structure introduced therein and has glucocorticoid receptor-binding activity | |
| CA2137523C (en) | One-pot process for the preparation of 3-quinolonecarboxylic acid derivatives | |
| RU2691728C2 (en) | Alkylation with an alkyl fluoroalkyl sulphate | |
| US20210070688A1 (en) | Carboxylate salt or sulfonate salt, and surfactant | |
| EP1798216A4 (en) | Intermediate of 6-substituted-1-methyl-1-h-benzimidazole derivative and method for producing same | |
| US6011170A (en) | Process for producing of cysteine derivatives | |
| EP2590940B1 (en) | New method for preparing ezetimibe | |
| JP3791015B2 (en) | Method for producing sulfonamide derivative | |
| RU96105392A (en) | METHOD OF OBTAINING HIV PROTEASE INHIBITORS | |
| WO2010141494A2 (en) | Synthesis of ezetimibe | |
| KR20060026445A (en) | Process for preparing intermediates useful to prepare certain antibacterial n-formyl hydroxylamines | |
| ES2407506T3 (en) | Procedure for the preparation of atorvastatin and intermediates used in said procedure | |
| BRPI0611838A2 (en) | process for the preparation of a compound | |
| JP3095549B2 (en) | Method for producing carbonate compound | |
| FR2494275A2 (en) | NEW DERIVATIVES OF VINYL-3 CEPHALOSPORINS AND THEIR PREPARATION | |
| US20120101271A1 (en) | Diamine synthesis via catalytic c-h amination of azides | |
| WO2016207915A1 (en) | Process for the preparation of ledipasvir | |
| KR950007920B1 (en) | Novel 4-ethoxycarbonyl-1-methylpyrazol-5-sulphon carbarmate derivatives and process for preparing thereof | |
| KR20010029474A (en) | Process to Prepare Pharmaceutical Compounds | |
| WO2021162070A1 (en) | Method for producing monomer for nucleic acid production |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |